The overall stock score is driven by strong financial performance and attractive valuation, with some caution due to technical indicators suggesting potential short-term volatility. The company's solid revenue growth and profitability are offset by concerns about cash flow and increased debt.
Positive Factors
Consistent revenue growth & margins
Shigematsu reports multi-year revenue growth and healthy gross and EBITDA margins, showing durable product demand and manufacturing efficiency. Sustained margins (gross 31.4%, EBITDA 12.6%) imply the core PPE business converts sales to operating profit, supporting reinvestment and competitive stability.
Solid balance sheet & moderate leverage
A moderate debt-to-equity ratio and near-50% equity ratio indicate capital structure resilience, providing flexibility for financing growth or managing cycles. ROE of 9.1% reflects acceptable returns on shareholder capital, underpinning long-term financial stability and ability to fund operations or strategic investments.
Defensive, recurring demand for PPE
Shigematsu's focus on respiratory PPE exposes it to structural, recurring demand driven by workplace safety rules and consumable replacement cycles. This business model provides stable revenue baselines and resilience to macro swings, as corporate and institutional buyers require ongoing product replenishment and compliance-driven purchases.
Negative Factors
Negative free cash flow due to capex
A materially negative free cash flow driven by heavy capital spending reduces cash cushions and increases reliance on financing or retained earnings. Over several quarters this can constrain dividend capacity, limit opportunistic investments, and require careful capex prioritization to avoid pressure on liquidity and credit metrics.
Rising total debt vs prior year
Although leverage is moderate, the recent increase in total debt raises refinancing and interest-cost risk if borrowing continues. If growth investments don't translate to improved operating cash conversion, higher debt could weaken flexibility, increase financial costs, and amplify downside in slower demand periods.
Limited operating margin headroom
An EBIT margin below larger industrial peers implies pressure on operating profitability and narrower buffers against cost inflation. Structural margin improvement will require efficiency gains or pricing power; absent those, slower margin expansion may constrain returns and make the company more sensitive to raw material or labor cost volatility.
Shigematsu Works Co., Ltd. (7980) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.38B
Dividend Yield1.93%
Average Volume (3M)7.97K
Price to Earnings (P/E)9.1
Beta (1Y)0.25
Revenue Growth4.41%
EPS Growth-16.07%
CountryJP
Employees386
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)32.29
Shares Outstanding7,200,000
10 Day Avg. Volume9,150
30 Day Avg. Volume7,966
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.67
Price to Sales (P/S)0.41
P/FCF Ratio-3.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shigematsu Works Co., Ltd. Business Overview & Revenue Model
Company DescriptionShigematsu Works Co., Ltd. manufactures and sells protective equipment in Japan. It offers protective clothing and gloves; eye protectors; reusable respirators; disposable respirators; powered air purifying respirators; supplied-air respirators; self-contained breathing apparatus; gas respirators/chemical cartridge respirators; face shields; earmuffs; safety belts; stretchers; and oxygen meters. The company is also involved in the manufacture and sale of instrument, chemical, and material related to safety and health, disaster-prevention in the plumbing and industrial fields. Shigematsu Works Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyThe company generates revenue primarily through the sale of its core products, including respirators, masks, and other safety equipment. Their revenue model includes direct sales to businesses in sectors like construction, manufacturing, and healthcare, as well as government contracts for public safety equipment. Significant partnerships with industrial companies and health organizations enhance their market reach and drive sales. Additionally, Shigematsu may benefit from recurring revenue through maintenance and service contracts related to their safety equipment, further contributing to their earnings.
Shigematsu Works Co., Ltd. Financial Statement Overview
Summary
Shigematsu Works Co., Ltd. demonstrates strong revenue growth and profitability with solid margins, supported by a stable balance sheet. However, the recent increase in debt and negative free cash flow due to capital investments pose potential risks.
Income Statement
85
Very Positive
Shigematsu Works Co., Ltd. has shown a strong revenue growth rate of 8.6% in the most recent year, with consistent improvements in gross and net profit margins. The gross profit margin stands at 31.4%, while the net profit margin is 5.5%, indicating efficient cost management and profitability. The EBITDA margin of 12.6% reflects a healthy operating performance. However, EBIT margin at 7.6% suggests room for operational cost optimization.
Balance Sheet
78
Positive
The company's balance sheet displays a solid equity base with a debt-to-equity ratio of 0.59, reflecting moderate leverage. The return on equity is 9.1%, indicating good profitability relative to shareholder investment. The equity ratio of 47.5% suggests a stable financial structure, though an increase in total debt from the previous year could be a potential risk factor if not managed properly.
Cash Flow
70
Positive
The cash flow analysis reveals a challenging year with a negative free cash flow of -1.65 billion yen, largely due to high capital expenditures. The operating cash flow to net income ratio of 0.29 indicates weaker cash generation from operations. The free cash flow to net income ratio is negative, highlighting the impact of capital investments on cash reserves, necessitating careful management of cash flow.
Breakdown
TTM
Mar 2025
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Income Statement
Total Revenue
14.08B
14.11B
13.00B
12.88B
11.92B
12.70B
Gross Profit
4.27B
4.43B
4.00B
4.09B
3.70B
4.09B
EBITDA
1.69B
1.77B
1.39B
1.77B
1.47B
1.40B
Net Income
666.27M
780.58M
584.08M
748.24M
589.11M
651.05M
Balance Sheet
Total Assets
17.98B
18.05B
16.10B
15.20B
14.32B
13.98B
Cash, Cash Equivalents and Short-Term Investments
1.46B
1.48B
1.63B
1.63B
1.35B
1.53B
Total Debt
4.84B
5.04B
3.12B
3.13B
3.36B
3.45B
Total Liabilities
9.32B
9.48B
7.81B
7.85B
7.83B
8.37B
Stockholders Equity
8.66B
8.57B
8.28B
7.35B
6.50B
5.62B
Cash Flow
Free Cash Flow
0.00
-1.65B
126.19M
573.95M
-7.55M
-349.35M
Operating Cash Flow
0.00
228.18M
966.39M
1.12B
490.66M
762.84M
Investing Cash Flow
0.00
-2.21B
-838.81M
-643.92M
-496.46M
-1.13B
Financing Cash Flow
0.00
1.83B
-125.72M
-299.93M
-173.66M
399.23M
Shigematsu Works Co., Ltd. Technical Analysis
Technical Analysis Sentiment
Positive
Last Price783.00
Price Trends
50DMA
807.62
Positive
100DMA
798.41
Positive
200DMA
803.92
Positive
Market Momentum
MACD
27.50
Negative
RSI
70.92
Negative
STOCH
61.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7980, the sentiment is Positive. The current price of 783 is below the 20-day moving average (MA) of 838.85, below the 50-day MA of 807.62, and below the 200-day MA of 803.92, indicating a bullish trend. The MACD of 27.50 indicates Negative momentum. The RSI at 70.92 is Negative, neither overbought nor oversold. The STOCH value of 61.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7980.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 28, 2025